JP Morgan Chase
CALC icon

JP Morgan Chase’s CalciMedica CALC Stock Holding History

JP Morgan Chase’s Portfolio CALC Stock Details CALC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15
Closed -$29 – 7119
2025
Q1 		$29 Sell
15
-2
-12% -$5 ﹤0.01% 7071
2024
Q4 		$60 Hold
17
– – ﹤0.01% 7092
2024
Q3 		$75 Sell
17
-1
-6% -$4 ﹤0.01% 7040
2024
Q2 		$71 Buy
18
+4
+29% +$20 ﹤0.01% 6958
2024
Q1 		$58 Buy
+14
New +$64 ﹤0.01% 7005
2022
Q4 		– Sell
-1
Closed – – 6573
2022
Q3 		$0 Buy
+1
New +$14 ﹤0.01% 6478
2022
Q2 		– Sell
-38
Closed -$1K – 6485
2022
Q1 		$1K Buy
+38
New +$724 ﹤0.01% 6458
2021
Q4 		– Sell
-7,698
Closed -$358K – 6666
2021
Q3 		$358K Buy
+7,698
New +$433K ﹤0.01% 4915
2021
Q2 		– Sell
-9,015
Closed -$701K – 6358
2021
Q1 		$701K Buy
9,015
+7,704
+588% +$2.31M ﹤0.01% 4463
2020
Q4 		$533K Buy
+1,311
New +$387K ﹤0.01% 4330

Other funds holding CALC

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIA
Wealthedge Investment Advisors New York $272M AUM 10.26% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

JP Morgan Chase's CALC Position: Q2 2025 in Review

JP Morgan Chase sold out of CalciMedica (CALC) in Q2 2025, closing a stake of 15 shares — an estimated $29 sold.

JP Morgan Chase first reported a position in CALC in Q4 2020 and held it in 10 quarters. The position peaked at $701K in Q1 2021. 30 funds tracked by Wall St. Rank hold CALC as of Q2 2025.

  • JP Morgan Chase reported no remaining CalciMedica position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 15 CalciMedica shares in Q2 2025, an estimated $29.
  • JP Morgan Chase first reported a position in CalciMedica in Q4 2020 and held it in 10 quarters.
  • JP Morgan Chase's CalciMedica position peaked at $701K in Q1 2021.
  • 30 funds tracked by Wall St. Rank held CalciMedica as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.